Business

Overseas Successes: Celltrion Launches in Canada, Wins Tender in Brazil

April 11th 2022

By Skylar Jeremias

Article

Republic of Korea-based Celltrion Healthcare launched its high-concentration adalimumab biosimilar in Canada and won several Brazilian tenders to supply its infliximab biosimilar.

Fresenius Kabi Steps Up Its Biosimilar Game With Biosimilar Approval in Europe, Acquisitions

April 9th 2022

By Skylar Jeremias

Article

Switzerland-based company Fresenius Kabi announced that its pegfilgrastim biosimilar received marketing authorization in Europe and that it has obtained a majority stake in biosimilar manufacturer mAbxience and acquired its subsidiary.

Improved Biosimilar Uptake Saved Health System $26.9M Over 2 Years

March 28th 2022

By Laura Joszt

Article

A series of initiatives to improve uptake of the biosimilars for 7 originator biologics resulted in significant savings for Providence St. Joseph Health.

Eye on Pharma: International Business Roundup

March 26th 2022

By Skylar Jeremias

Article

Alvotech and Fuji Pharma signed a deal for a biosimilar in Japan; Signet partnered with Juno Pharmaceuticals to grow equity investment; and Sandoz expanded its ability to produce generic respiratory drugs by acquiring Coalesce.

Companies Sign Manufacturing Agreements Aimed at Increasing Biosimilar Access, Affordability

March 16th 2022

By Skylar Jeremias

Article

OcyonBio signed a Good Manufacturing Practice (GMP) agreement for the manufacturing of biosimilars in Puerto Rico, while Evio Pharmacy Solutions implemented a strategy aimed at increasing biosimilar affordability.

Julie Reed on How the Biosimilars Forum Is Preparing for US Market Introduction of Adalimumab Biosimilar

March 13th 2022

By Skylar Jeremias

Video

Julie M. Reed, the new executive director of the Biosimilars Forum, shares how the Forum is preparing for the US market introduction of the first FDA-approved adalimumab biosimilars.

Prior Authorization Panel Yields Insights Into Role of PBMs in Biosimilar Uptake

March 9th 2022

By Mary Caffrey

Article

At a session at the Association of Community Cancer Centers’ 2022 Annual Meeting & Cancer Center Business Summit, panelists suggested that the quest for rebates by pharmacy benefit managers (PBMs) prevents uptake on some biosimilars—and could soon bleed over into biosimilar formulary placement.

AbbVie Settles ITC Case With Alvotech; Humira Biosimilar to Launch July 2023

March 8th 2022

By Skylar Jeremias

Article

AbbVie settles outstanding lawsuits, including its case related to the International Trade Commission (ITC), with Alvotech, giving Alvotech the green light to launch its high-concentration, citrate-free adalimumab biosimilar referencing Humira in July 2023, pending FDA approval.

Civica Initiates Project to Manufacture, Distribute Insulin Biosimilars for Uninsured Patients

March 7th 2022

By Skylar Jeremias

Article

Civica Rx will collaborate with companies to manufacture and distribute 3 insulin biosimilars and will offer them at an affordable price to uninsured and underinsured patients.

Henlius Collaborates With Getz Pharma for Adalimumab Biosimilar

March 5th 2022

By Skylar Jeremias

Article

Shanghai Henlius Biotech announced a commercialization agreement with Getz Pharma Limited for an adalimumab biosimilar for various African and Asian countries.